APA (7th ed.) Citation

Bailey, D. L., Willowson, K. P., Harris, M., Biggin, C., Aslani, A., Lengkeek, N. A., . . . Schembri, G. P. (2023). 64 Cu Treatment Planning and 67 Cu Therapy with Radiolabeled [ 64 Cu/ 67 Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry. Journal of Nuclear Medicine, 64(5), 704-710. https://doi.org/10.2967/jnumed.122.264586

Chicago Style (17th ed.) Citation

Bailey, Dale L., et al. "64 Cu Treatment Planning and 67 Cu Therapy with Radiolabeled [ 64 Cu/ 67 Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry." Journal of Nuclear Medicine 64, no. 5 (2023): 704-710. https://doi.org/10.2967/jnumed.122.264586.

MLA (9th ed.) Citation

Bailey, Dale L., et al. "64 Cu Treatment Planning and 67 Cu Therapy with Radiolabeled [ 64 Cu/ 67 Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry." Journal of Nuclear Medicine, vol. 64, no. 5, 2023, pp. 704-710, https://doi.org/10.2967/jnumed.122.264586.